Phathom Pharmaceuticals (PHAT) Competitors $10.90 +0.28 (+2.59%) Closing price 03:59 PM EasternExtended Trading$10.94 +0.04 (+0.32%) As of 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHAT vs. AMRX, RARE, KYMR, IMVT, HCM, XENE, ALVO, CRNX, GMTX, and CPRXShould you be buying Phathom Pharmaceuticals stock or one of its competitors? The main competitors of Phathom Pharmaceuticals include AMNEAL PHARMACEUTICALS (AMRX), Ultragenyx Pharmaceutical (RARE), Kymera Therapeutics (KYMR), Immunovant (IMVT), HUTCHMED (HCM), Xenon Pharmaceuticals (XENE), Alvotech (ALVO), Crinetics Pharmaceuticals (CRNX), Gemini Therapeutics (GMTX), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical products" industry. Phathom Pharmaceuticals vs. Its Competitors AMNEAL PHARMACEUTICALS Ultragenyx Pharmaceutical Kymera Therapeutics Immunovant HUTCHMED Xenon Pharmaceuticals Alvotech Crinetics Pharmaceuticals Gemini Therapeutics Catalyst Pharmaceuticals Amneal Pharmaceuticals (NASDAQ:AMRX) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations. Which has preferable valuation & earnings, AMRX or PHAT? Amneal Pharmaceuticals has higher revenue and earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmneal Pharmaceuticals$2.79B1.07-$116.89M$0.01952.80Phathom Pharmaceuticals$55.25M14.05-$334.33M-$4.73-2.31 Does the media refer more to AMRX or PHAT? In the previous week, Amneal Pharmaceuticals had 7 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 11 mentions for Amneal Pharmaceuticals and 4 mentions for Phathom Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.62 beat Phathom Pharmaceuticals' score of 0.29 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phathom Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals believe in AMRX or PHAT? 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 26.6% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 23.0% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, AMRX or PHAT? Amneal Pharmaceuticals has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Is AMRX or PHAT more profitable? Amneal Pharmaceuticals has a net margin of 0.12% compared to Phathom Pharmaceuticals' net margin of -289.51%. Phathom Pharmaceuticals' return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amneal Pharmaceuticals0.12% -189.49% 6.17% Phathom Pharmaceuticals -289.51%N/A -90.40% Do analysts rate AMRX or PHAT? Amneal Pharmaceuticals currently has a consensus target price of $11.60, indicating a potential upside of 21.75%. Phathom Pharmaceuticals has a consensus target price of $17.50, indicating a potential upside of 59.96%. Given Phathom Pharmaceuticals' higher possible upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than Amneal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amneal Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryAmneal Pharmaceuticals beats Phathom Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHAT vs. The Competition Export to ExcelMetricPhathom PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$776.30M$3.11B$5.75B$9.56BDividend YieldN/A2.23%4.53%4.07%P/E Ratio-2.3120.4030.4425.14Price / Sales14.05236.79391.6287.40Price / CashN/A42.3737.0358.50Price / Book-1.917.929.006.20Net Income-$334.33M-$54.72M$3.26B$265.38M7 Day Performance4.49%1.51%1.00%-1.13%1 Month Performance39.72%5.69%4.23%-0.70%1 Year Performance-15.72%8.83%28.45%18.99% Phathom Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHATPhathom Pharmaceuticals2.809 of 5 stars$10.91+2.6%$17.50+60.5%-16.6%$773.60M$55.25M-2.31110AMRXAMNEAL PHARMACEUTICALS3.2242 of 5 stars$8.84+3.5%$11.60+31.2%+16.2%$2.68B$2.79B884.888,100RAREUltragenyx Pharmaceutical4.6402 of 5 stars$27.39-0.5%$81.50+197.6%-44.6%$2.65B$560.23M-4.951,294KYMRKymera Therapeutics3.0233 of 5 stars$37.68-7.2%$59.11+56.9%-8.9%$2.65B$47.07M-12.15170High Trading VolumeIMVTImmunovant2.9164 of 5 stars$14.76-4.5%$35.33+139.4%-53.0%$2.64BN/A-5.39120HCMHUTCHMED2.6791 of 5 stars$15.48+3.2%$28.00+80.9%-11.6%$2.62B$630.20M0.001,811XENEXenon Pharmaceuticals2.0502 of 5 stars$34.11+2.0%$54.33+59.3%-4.7%$2.57B$9.43M-10.56210Options VolumeAnalyst RevisionALVOAlvotech2.6006 of 5 stars$8.52+0.7%$14.00+64.3%-35.0%$2.55B$491.98M23.031,032Trending NewsAnalyst DowngradeShort Interest ↓CRNXCrinetics Pharmaceuticals3.5231 of 5 stars$27.38+2.0%$68.86+151.5%-46.0%$2.53B$1.04M-6.66210News CoverageGMTXGemini TherapeuticsN/A$58.03+1.7%N/A+16.5%$2.51BN/A-58.0330CPRXCatalyst Pharmaceuticals4.9132 of 5 stars$19.68-0.9%$33.20+68.7%-1.7%$2.43B$491.73M11.9380Positive NewsAnalyst Downgrade Related Companies and Tools Related Companies AMNEAL PHARMACEUTICALS Alternatives Ultragenyx Pharmaceutical Alternatives Kymera Therapeutics Alternatives Immunovant Alternatives HUTCHMED Alternatives Xenon Pharmaceuticals Alternatives Alvotech Alternatives Crinetics Pharmaceuticals Alternatives Gemini Therapeutics Alternatives Catalyst Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHAT) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access